Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026
Company Deals

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026
Company Deals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026
Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Fineline Cube Aug 12, 2026
Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026
Company Drug

European Commission Grants Conditional Approval to Ipsen’s Ojemda (Tovorafenib) for Pediatric Low-Grade Glioma with BRAF Alterations

Fineline Cube Apr 23, 2026

Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced on April 22, 2026, that the European Commission...

Company Medical Device

Johnson & Johnson Secures CE Mark for Advanced ETHICON 4000 Surgical Stapler with Proprietary 3D Stapling Technology

Fineline Cube Apr 23, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced on April 22, 2026, that it has received...

Company Drug

FDA Approves Sanofi-Regeneron’s Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2–11 Years

Fineline Cube Apr 23, 2026

The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi (NASDAQ: SNY) and...

Company Drug

China’s CDE Releases 106th Batch of Chemical Generic Reference Preparations with 27 New Specifications and Updated Guidelines

Fineline Cube Apr 23, 2026

The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration has published the...

Company Drug

FDA Extends Review Timeline for Sanofi’s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026

Fineline Cube Apr 23, 2026

The U.S. Food and Drug Administration (FDA) has extended the target action date for its...

Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026

China’s National Medical Products Administration (NMPA) has announced the immediate suspension of imports of colchicine...

Company Drug

Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment

Fineline Cube Apr 22, 2026

Merck & Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration...

Company Deals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Fineline Cube Apr 22, 2026

Boji Medical Technology Co., Ltd. (SHE: 300404), a Chinese clinical research organization (CRO), has entered...

Company Drug

Roche’s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials

Fineline Cube Apr 22, 2026

Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that its investigational non-covalent Bruton’s tyrosine kinase (BTK)...

Company Deals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

Fineline Cube Apr 22, 2026

Novabio Therapeutics and OBiO Tech, Inc. (SHA: 688238) have expanded their strategic collaboration to accelerate...

Company Drug

Gan & Lee’s Nectin-4 ADC GLR1059 Clears Regulatory Hurdle for Solid Tumor Trials

Fineline Cube Apr 22, 2026

Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced it has received approval from China’s...

Company

Danaher Q1 Earnings Beat Expectations as Bioprocessing Strength Offsets Cepheid Weakness

Fineline Cube Apr 22, 2026

Danaher Corporation (NYSE: DHR) reported first-quarter 2026 revenues of $6.0 billion, up 3.5% year-over-year, with...

Company Drug

Leads Biolabs Enrolls First Patient in Phase II Trial for Gastric Cancer Drug Opamtistomig

Fineline Cube Apr 22, 2026

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced the first patient enrollment in a Phase...

Company Drug

Roche’s Gazyva Gains FDA Review Acceptance for Systemic Lupus Erythematosus Treatment

Fineline Cube Apr 22, 2026

Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration (FDA)...

Company Deals

InxMed Limited Files for Hong Kong IPO with Near-Commercial FAK Inhibitor Ifebemtinib

Fineline Cube Apr 22, 2026

InxMed Limited, a China-based late-stage clinical biotechnology company, has filed a prospectus for an initial...

Company Drug

Daiichi Sankyo and AstraZeneca Launch Datroway ADC in China for HR-Positive, HER2-Negative Breast Cancer

Fineline Cube Apr 22, 2026

Daiichi Sankyo Co., Ltd. (TYO: 4568) and AstraZeneca plc (NYSE: AZN) announced the commercial launch...

Company Drug

Merck and Eisai’s LITESPARK-012 Trial Fails to Meet Primary Endpoints in Advanced Kidney Cancer

Fineline Cube Apr 22, 2026

Merck & Co., Inc. (MSD, NYSE: MRK) and Eisai Co., Ltd. (TYO: 4523) announced that...

Company Drug

AstraZeneca’s Ultomiris Shows Significant Proteinuria Reduction in Phase III IgA Nephropathy Trial

Fineline Cube Apr 22, 2026

AstraZeneca plc (NYSE: AZN) announced positive results from a pre-specified interim analysis of the Phase...

Others

China’s Drug Quality Control System Shows 99.5% Compliance Rate in 2025 NMPA Report

Fineline Cube Apr 22, 2026

The National Medical Products Administration (NMPA) has released its National Drug Sampling Inspection Annual Report...

Company Deals

NeuroGen Pharma Secures Exclusive China Rights to Teva’s Ajovy – World’s First Dual-Indication CGRP Antagonist for Migraine Prevention

Fineline Cube Apr 22, 2026

NeuroGen Pharma announced a strategic licensing agreement with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), securing...

Posts pagination

1 … 52 53 54 … 707

Recent updates

  • Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal
  • NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib
  • Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million
  • Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026
  • Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal

Company Medical Device

NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.